191 related articles for article (PubMed ID: 35728990)
1. Previous biological therapy and impairment of the IFN-γ/IL-10 axis are associated with low immune response to 17DD-YF vaccination in patients with spondyloarthritis.
Casagrande TZ; Costa-Rocha IAD; Gavi MBRO; Miyamoto ST; Martins PC; Serrano ÉV; Dinis VG; Machado KLLL; Gouvea SA; Caser LC; Campi-Azevedo AC; Teixeira-Carvalho A; Peruhype-Magalhães V; Bissoli MF; Gouvea MDPG; Lima SMB; Miranda EH; Trindade GF; Lyra DGP; Burian APN; Neto LFDSP; da Mota LMH; Martins-Filho OA; Valim V
Vaccine; 2022 Jul; 40(32):4580-4593. PubMed ID: 35728990
[TBL] [Abstract][Full Text] [Related]
2. Serum biomarker profile orchestrating the seroconversion status of patients with autoimmune diseases upon planned primary 17DD Yellow fever vaccination.
da Costa-Rocha IA; Machado KLLL; Campi-Azevedo AC; Teixeira-Carvalho A; Peruhype-Magalhães V; de Lima SMB; Miranda EH; Trindade GF; Casagrande TZ; Miyamoto ST; Deotti SC; Barbosa RVR; Rocha PCM; Serrano EV; Dinis VG; Gouvêa SA; Gavi MBRO; da Silva LB; Duque RH; Gianordoli APE; Bissoli MF; Gouvea MDPG; Pinto-Neto LFDS; Burian APN; Fantinato FFST; Pileggi GS; da Mota LMH; Valim V; Martins-Filho OA
Sci Rep; 2021 May; 11(1):10431. PubMed ID: 34001945
[TBL] [Abstract][Full Text] [Related]
3. Planned Yellow Fever Primary Vaccination Is Safe and Immunogenic in Patients With Autoimmune Diseases: A Prospective Non-interventional Study.
Valim V; Machado KLLL; Miyamoto ST; Pinto AD; Rocha PCM; Serrano EV; Dinis VG; Gouvêa SA; Dias JGF; Campi-Azevedo AC; Teixeira-Carvalho A; Peruhype-Magalhães V; da Costa-Rocha IA; de Lima SMB; Miranda EH; Trindade GF; Maia MLS; Gavi MBRO; da Silva LB; Duque RH; Gianordoli APE; Casagrande TZ; Oliveira KG; Moura BCDM; Nicole-Batista F; Rodrigues LC; Clemente TB; Magalhães ES; Bissoli MF; Gouvea MDPG; Pinto-Neto LFDS; Costa CZ; Giovelli RA; Brandão LR; Polito ETL; Koehlert IO; Borjaille BP; Pereira DB; Dias LH; Merlo DL; Genelhu LFF; Pretti FZ; Giacomin MDS; Burian APN; Fantinato FFST; Pileggi GS; da Mota LMH; Martins-Filho OA
Front Immunol; 2020; 11():1382. PubMed ID: 32765496
[TBL] [Abstract][Full Text] [Related]
4. Subdoses of 17DD yellow fever vaccine elicit equivalent virological/immunological kinetics timeline.
Campi-Azevedo AC; de Almeida Estevam P; Coelho-Dos-Reis JG; Peruhype-Magalhães V; Villela-Rezende G; Quaresma PF; Maia Mde L; Farias RH; Camacho LA; Freire Mda S; Galler R; Yamamura AM; Almeida LF; Lima SM; Nogueira RM; Silva Sá GR; Hokama DA; de Carvalho R; Freire RA; Filho EP; Leal Mda L; Homma A; Teixeira-Carvalho A; Martins RM; Martins-Filho OA
BMC Infect Dis; 2014 Jul; 14():391. PubMed ID: 25022840
[TBL] [Abstract][Full Text] [Related]
5. Impact of synthetic and biological immunomodulatory therapy on the duration of 17DD yellow fever vaccine-induced immunity in rheumatoid arthritis.
Ferreira CC; Campi-Azevedo AC; Peruhype-Magalhāes V; Coelho-Dos-Reis JG; Antonelli LRDV; Torres K; Freire LC; da Costa-Rocha IA; Oliveira ACV; Maia MLS; de Lima SMB; Domingues CM; Teixeira-Carvalho A; Martins-Filho OA; da Mota LMH;
Arthritis Res Ther; 2019 Mar; 21(1):75. PubMed ID: 30871593
[TBL] [Abstract][Full Text] [Related]
6. 17DD and 17D-213/77 yellow fever substrains trigger a balanced cytokine profile in primary vaccinated children.
Campi-Azevedo AC; de Araújo-Porto LP; Luiza-Silva M; Batista MA; Martins MA; Sathler-Avelar R; da Silveira-Lemos D; Camacho LA; de Menezes Martins R; de Lourdes de Sousa Maia M; Farias RH; da Silva Freire M; Galler R; Homma A; Ribeiro JG; Lemos JA; Auxiliadora-Martins M; Caldas IR; Elói-Santos SM; Teixeira-Carvalho A; Martins-Filho OA
PLoS One; 2012; 7(12):e49828. PubMed ID: 23251351
[TBL] [Abstract][Full Text] [Related]
7. Exploratory study of humoral and cellular immunity to 17DD Yellow Fever vaccination in children and adults residents of areas without circulation of Yellow Fever Virus.
Reis LR; Costa-Rocha IAD; Campi-Azevedo AC; Peruhype-Magalhães V; Coelho-Dos-Reis JG; Costa-Pereira C; Otta DA; Freire LC; Lima SMB; Azevedo AS; Schwarcz WD; Ano Bom APD; Silva AMVD; Souza AF; Castro TDM; Ferroco CLV; Filippis AMB; Nogueira FB; Homma A; Domingues CM; Sousa ESS; Camacho LAB; Maia MLS; Teixeira-Carvalho A; Martins-Filho OA
Vaccine; 2022 Jan; 40(5):798-810. PubMed ID: 34969545
[TBL] [Abstract][Full Text] [Related]
8. Booster dose after 10 years is recommended following 17DD-YF primary vaccination.
Campi-Azevedo AC; Costa-Pereira C; Antonelli LR; Fonseca CT; Teixeira-Carvalho A; Villela-Rezende G; Santos RA; Batista MA; Campos FM; Pacheco-Porto L; Melo Júnior OA; Hossell DM; Coelho-dos-Reis JG; Peruhype-Magalhães V; Costa-Silva MF; de Oliveira JG; Farias RH; Noronha TG; Lemos JA; von Doellinger Vdos R; Simões M; de Souza MM; Malaquias LC; Persi HR; Pereira JM; Martins JA; Dornelas-Ribeiro M; Vinhas Ade A; Alves TR; Maia Mde L; Freire Mda S; Martins Rde M; Homma A; Romano AP; Domingues CM; Tauil PL; Vasconcelos PF; Rios M; Caldas IR; Camacho LA; Martins-Filho OA
Hum Vaccin Immunother; 2016; 12(2):491-502. PubMed ID: 26360663
[TBL] [Abstract][Full Text] [Related]
9. Short-Lived Immunity After 17DD Yellow Fever Single Dose Indicates That Booster Vaccination May Be Required to Guarantee Protective Immunity in Children.
Campi-Azevedo AC; Reis LR; Peruhype-Magalhães V; Coelho-Dos-Reis JG; Antonelli LR; Fonseca CT; Costa-Pereira C; Souza-Fagundes EM; da Costa-Rocha IA; Mambrini JVM; Lemos JAC; Ribeiro JGL; Caldas IR; Camacho LAB; Maia MLS; de Noronha TG; de Lima SMB; Simões M; Freire MDS; Martins RM; Homma A; Tauil PL; Vasconcelos PFC; Romano APM; Domingues CM; Teixeira-Carvalho A; Martins-Filho OA
Front Immunol; 2019; 10():2192. PubMed ID: 31616412
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity and safety of primary fractional-dose yellow fever vaccine in autoimmune rheumatic diseases.
Tonacio AC; do Nascimento Pedrosa T; Borba EF; Aikawa NE; Pasoto SG; Filho JCRF; Sampaio Barros MM; Leon EP; Lombardi SCFS; Junior AM; Azevedo AS; Schwarcz WD; Fuller R; Yuki EFN; Ugolini Lopes MR; Rodrigues Pereira RM; Sampaio Barros PD; de Andrade DCO; de Medeiros-Ribeiro AC; de Moraes JCB; Shinjo SK; Miossi R; da Silva Duarte AJ; Lopes MH; Kallás EG; Almeida da Silva CA; Bonfá E
PLoS Negl Trop Dis; 2021 Nov; 15(11):e0010002. PubMed ID: 34843469
[TBL] [Abstract][Full Text] [Related]
11. Multi-parameter approach to evaluate the timing of memory status after 17DD-YF primary vaccination.
Costa-Pereira C; Campi-Azevedo AC; Coelho-Dos-Reis JG; Peruhype-Magalhães V; Araújo MSS; do Vale Antonelli LR; Fonseca CT; Lemos JA; Malaquias LCC; de Souza Gomes M; Rodrigues Amaral L; Rios M; Chancey C; Persi HR; Pereira JM; de Sousa Maia ML; Freire MDS; Martins RM; Homma A; Simões M; Yamamura AY; Farias RHG; Romano APM; Domingues CM; Tauil PL; Vasconcelos PFC; Caldas IR; Camacho LA; Teixeira-Carvalho A; Martins-Filho OA
PLoS Negl Trop Dis; 2018 Jun; 12(6):e0006462. PubMed ID: 29879134
[TBL] [Abstract][Full Text] [Related]
12. Cynomolgus macaques as a translational model of human immune responses to yellow fever 17D vaccination.
Mantel N; Piras-Douce F; Chautard E; Marcos-Lopez E; Bodinham CL; Cosma A; Courtois V; Dhooge N; Gautheron S; Kaufmann SHE; Pizzoferro K; Lewis DJM; Martinon F; Pagnon A; Raynal F; Dereuddre-Bosquet N; Le Grand R
J Virol; 2024 May; 98(5):e0151623. PubMed ID: 38567951
[TBL] [Abstract][Full Text] [Related]
13. 17DD Yellow Fever Revaccination and Heightened Long-Term Immunity in Populations of Disease-Endemic Areas, Brazil.
Campi-Azevedo AC; Peruhype-Magalhāes V; Coelho-Dos-Reis JG; Antonelli LR; Costa-Pereira C; Speziali E; Reis LR; Lemos JA; Ribeiro JGL; Bastos Camacho LA; de Sousa Maia ML; Barbosa de Lima SM; Simões M; de Menezes Martins R; Homma A; Cota Malaquias LC; Tauil PL; Costa Vasconcelos PF; Martins Romano AP; Domingues CM; Teixeira-Carvalho A; Martins-Filho OA;
Emerg Infect Dis; 2019 Aug; 25(8):1511-1521. PubMed ID: 31298654
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive landscape of neutralizing antibody and cell-mediated response elicited by the 1/5 fractional dose of 17DD-YF primary vaccination in adults.
Reis LR; Costa-Rocha IA; Abdala-Torres T; Campi-Azevedo AC; Peruhype-Magalhães V; Araújo MSS; Spezialli E; do Valle Antonelli LR; da Silva-Pereira RA; Almeida GG; Fernandes EG; Fantinato FFST; Domingues CMAS; Lemos MCF; Chieppe A; Lemos JAC; Coelho-Dos-Reis JG; de Lima SMB; de Souza Azevedo A; Schwarcz WD; Camacho LAB; de Lourdes de Sousa Maia M; de Noronha TG; Duault C; Rosenberg-Hasson Y; Teixeira-Carvalho A; Maecker HT; Martins-Filho OA;
Sci Rep; 2024 Apr; 14(1):7709. PubMed ID: 38565882
[TBL] [Abstract][Full Text] [Related]
15. Seroconversion and antibody persistence after yellow fever vaccination in people living with HIV: impact of baseline HIV viral load and yellow fever seropositivity.
Martin C; Florence E; Domingo C; Delforge M; De Wit S; Dauby N
J Travel Med; 2022 Dec; 29(8):. PubMed ID: 35285913
[TBL] [Abstract][Full Text] [Related]
16. Persistence of yellow fever virus-specific neutralizing antibodies after vaccination among US travellers.
Lindsey NP; Horiuchi KA; Fulton C; Panella AJ; Kosoy OI; Velez JO; Krow-Lucal ER; Fischer M; Staples JE
J Travel Med; 2018 Jan; 25(1):. PubMed ID: 30346562
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of humoral immune response after yellow fever infection: an observational study on patients from the 2017-2018 sylvatic outbreak in Brazil.
Gonçalves AP; Almeida LT; Rezende IMd; Fradico JRB; Pereira LS; Ramalho DB; Pascoal Xavier MA; Calzavara Silva CE; Monath TP; LaBeaud AD; Drumond BP; Campi-Azevedo AC; Martins-Filho OA; Teixeira-Carvalho A; Alves PA;
Microbiol Spectr; 2024 May; 12(5):e0370323. PubMed ID: 38511952
[TBL] [Abstract][Full Text] [Related]
18. A randomised double-blind clinical trial of two yellow fever vaccines prepared with substrains 17DD and 17D-213/77 in children nine-23 months old.
Collaborative Group for Studies of Yellow Fever Vaccine
Mem Inst Oswaldo Cruz; 2015 Sep; 110(6):771-80. PubMed ID: 26517656
[TBL] [Abstract][Full Text] [Related]
19. 17DD yellow fever vaccine: a double blind, randomized clinical trial of immunogenicity and safety on a dose-response study.
Martins RM; Maia Mde L; Farias RH; Camacho LA; Freire MS; Galler R; Yamamura AM; Almeida LF; Lima SM; Nogueira RM; Sá GR; Hokama DA; de Carvalho R; Freire RA; Pereira Filho E; Leal Mda L; Homma A
Hum Vaccin Immunother; 2013 Apr; 9(4):879-88. PubMed ID: 23364472
[TBL] [Abstract][Full Text] [Related]
20. Sanger-based sequencing technology for yellow fever vaccine genetic quality control.
Pestana CP; Lawson-Ferreira R; Lessa-Aquino C; Leal MDLF; Freire MDS; Homma A; Medeiros MA
J Virol Methods; 2018 Oct; 260():82-87. PubMed ID: 30009851
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
